Loading…
Intellia Therapeutics, Inc. is projected to rise to $18.34 by 2027, a +19% move from its current price of $15.44. NTLA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $14.81 | $15.45 | $16.13 | +0.08% |
| Jul 14 | $14.56 | $15.47 | $16.43 | +0.16% |
| Jul 15 | $14.37 | $15.48 | $16.67 | +0.25% |
| Jul 16 | $14.22 | $15.49 | $16.87 | +0.33% |
| Jul 17 | $14.09 | $15.50 | $17.06 | +0.41% |
| Jul 18 | $13.97 | $15.52 | $17.23 | +0.49% |
| Jul 19 | $13.87 | $15.53 | $17.39 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.87 | $15.53 | $17.39 | +0.57% |
| Week 2 | $13.31 | $15.62 | $18.33 | +1.15% |
| Week 3 | $12.91 | $15.71 | $19.10 | +1.73% |
| Week 4 | $12.60 | $15.80 | $19.81 | +2.31% |
| Week 5 | $12.34 | $15.89 | $20.46 | +2.90% |
| Week 6 | $12.11 | $15.98 | $21.08 | +3.49% |
| Week 7 | $11.92 | $16.07 | $21.67 | +4.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company provides a modular platform to advance in vivo and ex vivo therapies for diseases.
Its in vivo product candidates include NTLA-2001 for the treatment of transthyretin amyloidosis and NTLA-2002 for the treatment of hereditary angioedema. It also offers product candidates for immuno-oncology and autoimmune diseases, with multiple in vivo programs to address diseases by delivering gene editing therapeutics to organs outside the liver.
Intellia has license and collaboration agreements with AvenCell Therapeutics, Kyverna Therapeutics, ONK Therapeutics, and ReCode Therapeutics, as well as collaborations with Regeneron Pharmaceuticals, SparingVision, and Rewrite Therapeutics. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc.
in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics, Inc. (NTLA) is a clinical-stage genome editing company. The current price is $15.44, and the company has a market cap of $2.16B. It is ranked 1996.
The stock’s price outlook is informed by a year-by-year forecast that starts at a neutral 2026 and becomes increasingly bullish through 2050, with projected average prices rising from $15.44 in 2026 to $115.36 in 2050.
In 2026 the forecast shows an average of $15.44 with a range from $9.21 to $22.52 (neutral sentiment). From 2027 onward, the forecast depicts a bullish trajectory, with progressively higher average prices and rising ROI, culminating in $115.36 average by 2050 and a forecasted ROI of 647.2%.
A major floor 41.8% below — a decisive break under it would weaken the trend.
The nearest floor, 21.6% below — buyers have tended to step in here.
The nearest ceiling, 15.5% above — a clean break opens room to run.
A major ceiling 32.5% above — clearing it would confirm fresh momentum.
Key NTLA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NTLA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.35 | Sell | $15.80 | Sell |
| MA 10 | $16.68 | Sell | $16.10 | Sell |
| MA 20 | $15.71 | Sell | $15.72 | Sell |
| MA 50 | $14.28 | Buy | $14.77 | Buy |
| MA 100 | $13.94 | Buy | $14.07 | Buy |
| MA 200 | $13.72 | Buy | $13.56 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.20 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -83.86 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | -6.79 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.84 | Buy |
| Awesome (5,34) | 1.66 | Buy |
| Ultimate (7,14,28) | 30.06 | Neutral |
| Momentum (10) | -1.82 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 15.52 | Sell |
| ADX (14) | 20.66 | Sell |
| ATR (14) | 0.60 | Info |
The current technical setup shows bullish sentiment overall, with mixed momentum indicators.
RSI14 is 50, suggesting neutral momentum around the midpoint. The 50-day simple moving average is $14.26 and the 200-day simple moving average is $13.74, indicating the price is trading above longer-term averages.
Key support is at $12.11 and resistance at $17.84. The 30-day price range spans from $11.82 to $20.17, illustrating recent volatility within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.21 | $15.44 | $22.55 | 0% | Neutral | |
| $13.83 | $18.34 | $26.13 | +19% | Neutral | |
| $14.30 | $19.86 | $29.85 | +29% | Bullish | |
| $13.54 | $19.55 | $30.62 | +27% | Bullish | |
| $12.94 | $19.35 | $31.36 | +25% | Bullish | |
| $14.86 | $22.96 | $38.33 | +49% | Bullish | |
| $18.29 | $29.15 | $49.97 | +89% | Bullish | |
| $20.47 | $33.59 | $58.97 | +118% | Bullish | |
| $19.58 | $33.04 | $59.27 | +114% | Bullish | |
| $19.44 | $33.71 | $61.71 | +118% | Bullish | |
| $27.05 | $53.29 | $105.98 | +245% | Bullish | |
| $38.04 | $84.53 | $189.14 | +448% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.21 | $15.44 | $18.60 | +0.00% |
| August 2026 | $13.33 | $15.98 | $19.85 | +3.51% |
| September 2026 | $13.72 | $16.63 | $21.01 | +4.08% |
| October 2026 | $13.32 | $16.30 | $20.88 | -1.99% |
| November 2026 | $13.16 | $16.24 | $21.05 | -0.37% |
| December 2026 | $13.84 | $17.21 | $22.55 | +5.96% |
Click any year to see its month-by-month NTLA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NTLA price prediction for 2026 points to an average of $15.44 (low $9.21, high $22.55) — a potential gain of 0% on today's $15.44. Price action looks broadly range-bound.
In 2027, NTLA is projected to trade between $13.83 and $26.13, averaging $18.34 — a potential gain of +19% from today's $15.44. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
Intellia Therapeutics, Inc.'s 2028 outlook centres on $19.86, within a $14.30 to $29.85 range. That is up +8% on the projected 2027 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2029, NTLA could reach as high as $30.62, with a base case around $19.55 and support toward $13.54 — roughly +27% from $15.44. Buyers look set to stay in control over this stretch.
Expect NTLA to range from $12.94 to $31.36 through 2030. The $19.35 average target implies a +25% move from current prices. That is -1% versus the projected 2029 average. Momentum favours further upside here.
The NTLA price prediction for 2031 points to an average of $22.96 (low $14.86, high $38.33) — a potential gain of +49% on today's $15.44. Buyers look set to stay in control over this stretch.
In 2032, NTLA is projected to trade between $18.29 and $49.97, averaging $29.15 — a potential gain of +89% from today's $15.44. That is up +27% on the projected 2031 average. Momentum favours further upside here.
Intellia Therapeutics, Inc.'s 2033 outlook centres on $33.59, within a $20.47 to $58.97 range. That is up +15% on the projected 2032 average. That marks a +118% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, NTLA could reach as high as $59.27, with a base case around $33.04 and support toward $19.58 — roughly +114% from $15.44. Momentum favours further upside here.
Expect NTLA to range from $19.44 to $61.71 through 2035. The $33.71 average target implies a +118% move from current prices. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The NTLA price prediction for 2040 points to an average of $53.29 (low $27.05, high $105.98) — a potential gain of +245% on today's $15.44. Momentum favours further upside here.
In 2050, NTLA is projected to trade between $38.04 and $189.14, averaging $84.53 — a potential gain of +448% from today's $15.44. That is up +59% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NTLA today (≈ 64.766839 NTLA) could be worth
$5,475.05
+$4,475.05 (+448%) by 2050 · US Dollar
Based on the average projected NTLA price of $84.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NTLAwould be worth at today's price.
$1,000 invested in NTLA on Jul 10, 2025 (≈ 82.236843 NTLA) would be worth
$1,269.74
+$269.74 (+27.0%) today · 1.27× · US Dollar
Based on a NTLA entry price of $12.16 vs. today's $15.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.56 | $879.27 | -12.1% |
| 1 month ago | $12.2 | $1,265.57 | +26.6% |
| 3 months ago | $13.49 | $1,144.55 | +14.5% |
| 6 months ago | $11.43 | $1,350.83 | +35.1% |
| 1 year ago | $12.16 | $1,269.74 | +27.0% |
| All time (5.0y) ago | $143.42 | $107.66 | -89.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NTLA forecast.
Our base-case forecast reaches $31.00 around 2033.
Implied market cap at $31.00: $4.33B
The multi-year forecast paints a bullish long-term path for NTLA, with rising average prices and higher potential ROI across the years.
In 2030, the average forecast price is $21.81, with a minimum of $14.81 and a maximum of $34.83, yielding an estimated ROI of 41.3% and a bullish sentiment. The trajectory continues higher in subsequent years, with 2040 projecting an average of $68.08 and a maximum of $132.44 (ROI 340.9%), and 2050 projecting an average of $115.36 and a maximum of $251.65 (ROI 647.2%).
Across 2027–2050 the forecast maintains a bullish tone, with rising averages and meaningful upside potential, while the year 2026 remains neutral at the average price of $15.44. These are estimates, not guarantees, and actual outcomes may differ due to market conditions and other factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $21.81, with a low of $14.81 and a high of $34.83, representing an estimated ROI of 41.3% and a bullish sentiment.
The forecast indicates a bullish trajectory from 2027 onward, with rising average prices (e.g., $18.78 in 2027, $27.04 in 2031, $34.65 in 2032, up to $115.36 in 2050) and positive ROI in later years (e.g., 21.6% in 2027, 41.3% in 2030, 340.9% in 2040, 647.2% in 2050), though 2026 is neutral. These are estimates and not guarantees.
Yes. The forecast shows a 2040 maximum of $132.44 and a 2050 maximum of $251.65, so a $100 target is within the forecasted range (2040 max $132.44). The 2040 average is projected at $68.08.
Current price is $15.44 and market cap is $2.16B.
The 30-day range is $11.82 to $20.17.
Intellia Therapeutics, Inc. Community Discussion
0Share your Intellia Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.